कभी कभी ऐसा देखा जाता है कि तैल की मालिश करने पर भी जोड़ो के दर्द में आराम नही होता या कभी कभी और बढ़ जाता है। जोड़ों के इस तरह के दर्द को आयुर्वेद में आमवात के नाम से जाना जाता है। यह रोग स्त्रियों में अधिक देखा जाता है। इसका मुख्य कारण भोजन
पाचन शक्ति में गइ़बड़ी होना है।
लक्षण (कैसे पहचाने)
ज्यादातर उंगलियो के जोड़ो में, अंगूठे के मूल में, मन्या, पैर के अँगूठे और घुटनों में दर्द
होना व सूजन होना
हल्का हलका बुखार बना रहना
सुबह बिस्तर से उठने के बाद शरीर में आलसी और अकड़न रहना
पेशाब बार बार लगना
पेट साफ न होना , हमेशा सुस्त सुस्त लगना
इस वात रोग में दर्द की शुरुवात छोटी सन्धियों से जैसे कि उंगलियों के जोड़ो से होती है।
फिर धीरे धीरे बढ़कर शरीर के सभी जोड़ों में फैल जाती है ।
ऐसे रोगी के लिए हलचल करना मुश्किल होता है।
घुटनो पर केवल छूने मात्र से जोरदार दर्द होता है।
इसका यदि सही इलाज न किया गया तो आगे जाकर उंगलियो में टेढ़ापन, हृदय रोग
आदि कई खतरनाक रोग होसकते है।
आमवात के कारण
गलत खान पान व असमय खानपान
उपवास अधिक करना
नियमित बासी भोजन खाना
ज्यादा मात्रा में नियमित तैलीय पदार्थ खाना
अत्यधिक ठंडी चीजे जैसे कुल्फी,कोल्ड्रिंक, फ़ास्ट फूड दही,चावल इत्यादि खाना
व्यायाम बिल्कुल न करना या अतिमात्रा में व्यायाम करना
वयानुसर हड्डियों की गुणवता में कमी होना
भोजन के तुरंत बाद आराम करना
ठंड स्थान या AC, कूलर के आगे काफी समय से सोने की वजह से
वजन ज्यादा होने की वजह से सन्धियों पर भार ज्याद होना
कभी कोई चोट या आघात की सही तरिके से ईलाज न करना
महिलाएं यदि डिलीवरी के बाद डॉक्टर के बताए नियमो के पालन न करने की वजह से
बार बारखाना ,अति मात्रा में या गलत चीजें खाना जिससे पाचन क्रिया बिगड़ कर
आमवात में परिवर्तित होजाता है।
ज्यादातर महिलाओं में जिनकी उम्र 40 वर्ष से ऊपर है , जिनके परिवार में किसी को यह
रोग हुआ हो उन्हें ज्यादा खतरा होता है।
ऐसे व्यक्ति धूमपान, मद्यपान करते है तो उनका रोग और बलवान होजाता है।
डॉक्टर को दिखाने का समय
जब चलते समय जोड़ो में दर्द बहुत अधिक होगया हो
चलने में उठकर बैठने में दर्द, सूजन आने पर या फिर जोड़ो की जगह पर होगयी हो ,तो
तुरंत वैद्य /चिकित्सक के पास जाएं।
हल्का बुखार और जोड़ो का दर्द कई दिनों से हो और ठीक न हो रहा हो तो तुरंत
चिकित्सक के पास जाए।
कौन-कौनसी जांच करवाना जरूरी
X-ray- ग्रस्त सन्धियों का X-ray करवाना जरूरी है,इससे यह पता लगेगा कि उस स्थान
पर कोई विकृति तो नही हुई है।
Rh फैक्टर आमवात की निश्चिती करने के लिए
रक्त जांच- रक्त कमी ,या अन्य कोई इंफेक्शन का पता लगाने के लिए।
Bone Mass Density- अस्थियों की गुणवता जांचने के लिए
आमवात से बचने के इपाय
भोजन के नियमों का पालन करे
सही तरीके से नियमित व्यायाम करें
अपने शरीर प्रमाण व बल के अनुसार वजन बना कर रखे
कोई चोट लगी हो तो तूरंत अच्छे से उसका उवचार करवाये।
आमवात ठीक करने के लिए घरेलू उपचार
गर्म पानी पिये
2 लीटर पानी मे 20 gm कृचला हुआ आद्रक या 10 gm पिसी हुई शोठ मिलाकर उबाले।
जब आधा शेष रहे तो ठंडा होने पर पिये।
लहसुन 10-15gm, गुड़ 2gm चटनी बनाकर खाये
रेत और नमक की पोटलियों से जोड़ो पर सेक करे।
मेथी दाना ,कलौंजी अजवायन चूर्ण मिलाकर 1 चम्मच सुबह शाम ले।
सावधान, अगर इन सब का प्रयोग करने पर भी कुछ दिनों में आराम न मिलता हो तो
तुरंत वैद्य या डॉक्टर की सलाह ले।
यह खाएं -ऐसे पदार्थ जिनमे vitamin D ज्यादा हो जैसे अंडा,चीज ,मशरुम आदि.,इनका
अपने भोजन में समावेश करे।
यह न खाएं -सलाद, ठन्डी चीजे,आइसक्रीम,ठंड पेय,केक,फ़ास्ट फूड दही
,चावल,घी,तैलीय पदार्थ जैसी चीजें न ले। सब्जियों में अरबी ,भिंडी आलू टमाटर न
नियमित हल्का व्यायाम करें। पैदल चले।
शरीर को गर्म रखे।
शरीर का भार अनुपात में रखे।
भोजन के तुरंत बाद या दिन में न सोयें।
ठंडे पानी से स्नान , या ठन्डी जगहों पर वास न करे
किसी भी प्रकार की दवाई लेने से पहले डॉक्टर से सलाह लेना आवश्यक है। आयुर्वेद के अनुभवी डॉक्टर से निशुल्क: परामर्श लें @ +91-9205773222
Rheumatoid arthritis, commonly known in Hindi as "Gatiya", is a disease of our own dysfunctional immune system. When I say dysfunctional immune system, it means that our own body and immune system which is meant to protect us from other infections and foreign invaders, starts attacking us back.
One percent of India's population has rheumatoid arthritis. Considering the large number of population we have, if we calculate almost 10 lac people are affected by it.
People often have this conception that it is the disease of the elderly and we as a young individual should not be having it. To broadly identify it, we have two types of arthritis. One is the age related one known as Osteoarthritis where there is more of wear and tear of cartilage. Osteoarthritis is a disease of the elderly.
The other arthritis is the inflammatory arthritis, which has fifty different variants with Rheumatoid arthritis being one of them. Rheumatoid arthritis affects most of the people in the younger age group between 20-40 and is more common in the girls. Arthritis in itself can affect the children as young as 6 months of age, known as Juvenile Idiopathic arthritis. So it doesn't really spare any age group.
But it is very important to be aware of the signs and symptoms of the disease. Only then you can approach your Rheumatologist early and help in arresting the disease at an early stage. One of the first signs is pain and stiffness in the hand joints (wrist, knuckles) and foot joints. One very peculiar feature of this arthritis is the early morning stiffness. You feel the hands and body are stiff in the mornings and takes you more than 30-45 minutes to get back to daily routine.
The stiffness goes down as day passes only to worsen at night again. And this is the exact time we should intervene and halt the disease . Eventually within 4-6 weeks of these symptoms you will start experiencing the swelling of the joints and progression to the large joints like knees, shoulders, elbows. Those are the early signs that the disease has progressed. All the new data points towards early control of disease, within six months of onset. People who start treatment late have more intake of pain killers and higher chances of joint damage. Rheumatoid arthritis does not limit to the joints only. It can affect lungs, kidneys, eyes as well.
Coming to the most important aspect is the treatment. There have been a lot of advances in the recent years but we still havnt been able to find the ultimate cure for it. One of the main goals which has changed over years is to use almost negligible pain killers and minimum steroids. We prefer avoiding steroids in our prescription. The drugs are divided into DMARDS and Biological DMARDS. 90 percent will respond to the traditional old DMARD Drugs (Methotrexate, LEflunomide, Hydroxychloroquine and Sulphasalzine) while 10 percent with aggressive disease may need the help of the Biological drugs.
As with alternative medicines, I will not comment much but to my experience it doesn't really help patients with moderate to severe disease and we end up losing crucial time to control the disease. Patients with mild disease may benefit a little from it. Ultimate goal remains to minimize the damage caused to the joints, provide good quality of life and avoidance of pain killers and steroids.
Apart from the medications, lifestyle modifications are very much needed to keep the disease at bay. Make sure you exercise daily for 20-30 minutes, avoid smoking and eathygienic food which should be well cooked. stress has been found to be a major culprit in triggering autoimmune diseases. We should learn the art of stress coping strategies to lead a well nurtured balanced life.
(Dr Naval Mendiratta, Consultant, Rheumatology, Fortis Memorial Research Institute, Gurugram)
New York, June 23 (IANS) Researchers at The University of Texas Health Science Center at Houston (UTHealth) in the US are studying the effectiveness of an arthritis drug in treating a type of severe immune overreaction seen in patients with Covid-19 induced pneumonia in a Phase 3 clinical trial.The clinical trial is enrolling patients at the Harris Health System's Lyndon B. Johnson Hospital in Houston, Texas.The Phase 3 study is evaluating the effectiveness of the drug canakinumab, an interleukin-1 (IL-1) blocker approved for the treatment of juvenile rheumatoid arthritis, for preventing cytokine release syndrome (CRS) in Covid-19 patients with pneumonia.Often referred to as a cytokine storm, CRS is a life-threatening immune reaction caused by the body releasing too many cytokines into the blood at once.Cytokines include a broad category of proteins secreted by the body.Interleukin-1 serves as the first-line defence for the immune system, alerting other proteins to respond if a virus or bacteria are present.Canakinumab blocks the production of IL-1 protein, which could prevent a possible deadly overreaction of the immune system in Covid-19 patients.Research has linked a number of Covid-19 deaths to CRS due to damage caused to several major organs.Roberto C. Arduino, MD, the study's lead investigator and professor of infectious disease at the McGovern Medical School in UTHealth, said this is a time for the HIV research community to utilise the members' expertise in the search for a treatment for coronavirus. Arduino's research background includes the study of new antiretroviral drugs, treatment strategies, immune activation, and inflammation in the search of an HIV cure."The research community truly feels compelled to do something in the search for a viable treatment for Covid-19, and I feel I owe it to my community to offer my expertise," said Arduino, who has led HIV clinical research for 22 years.Researchers are investigating if canakinumab combined with standard-of-care treatment can increase the chances of survival without ever requiring invasive mechanical ventilation in patients with Covid-19-induced pneumonia.Over a two-hour period, patients who are enrolled will receive either a 450 mg, 600 mg, or a 750 mg IV dose of canakinumab based on their body weight, UTHealth said in a statement on Monday. Arduino is the study's lead investigator.All participants will be monitored for up to 29 days, or until they are discharged from the hospital. A follow-up will occur at 127 days.--IANSgb/arm
New York, May 5 (IANS) People at high risk for knee osteoarthritis (OA) may be nervous and reluctant to participate in strenuous physical activities but a new study, which followed high-risk individuals for 10 years, showed that vigorous exercise did not increase their risk of developing OA and may even protect them from the condition.Osteoarthritis is the most common joint disorder in the US, affecting an estimated 32.5 million adults, according to the Centers for Disease Control and Prevention (CDC). The knee is the most commonly affected joint.The lifetime risk of developing symptomatic, radiographic knee OA (as diagnosed on an x-ray) is approximately 38 per cent to 45 per cent. The estimated median age of diagnosis is 55 years."Our findings convey a reassuring message that adults at high risk for knee OA may safely engage in long-term strenuous physical activity at a moderate level to improve their general health and well-being," said study researcher Alison Chang from Northwestern University in the US.In this observational study of 1,194 persons at high risk for but without radiographic evidence of knee OA who were followed for up to 10 years, long-term participation in strenuous physical activities was not associated with risk of developing radiographic knee OA. In fact, the vigorously exercising individuals in the study were 30 per cent less likely to develop OA, although the number was not considered statistically significant.The activities included jogging, swimming, cycling, singles tennis, aerobic dance and skiing. Persistent extensive sitting was not associated with either elevated or reduced risk.The researchers' analysis showed nearly 50 per cent of the adults at high risk for this disease did not engage in any strenuous physical activity over eight years."People suffering from knee injuries or who had arthroscopic surgical repair of ACL or meniscus are often warned that they are well on the path to developing knee OA," Chang said."They may be concerned that participating in vigorous activities or exercises could cause pain and further tissue damage. To mitigate this perceived risk, some have cut down or discontinued strenuous physical activities, although these activities are beneficial to physical and mental health," Chang added.The study, published in the journal JAMA Network Open, revealed that adults at high risk for knee OA may safely engage in long-term strenuous physical activity at a moderate level.--IANSbu/na
Paris, April 28 (IANS) With different approaches to treating Covid-19 patients being tried, varying results of two different arthritis drug trials on patients have further complicated the search for a cure.While makers of the drug Kevzara (sarilumab) found that it proved to be less effective in treating "severe" respiratory illness caused by Covid-19 as compared to the "critical patients in trials conducted in the US", another drug Actemra (tocilizumab) showed benefit in treating seriously ill patients in a trial in France.Announcing the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzara, Sanofi and Regeneron Pharmaceuticals Inc. on Monday said that Kevzara had no notable benefit on clinical outcomes when combining the "severe" and "critical" groups, versus placebo.However, there were negative trends for most outcomes in the "severe" group, while there were positive trends for all outcomes in the "critical" group, the results showed.Following a review by the Independent Data Monitoring Committee (IDMC) of all available Phase 2 and Phase 3 data, the trial will be immediately amended so that only "critical" patients continue to be enrolled to receive Kevzara 400 mg or placebo, Sanofi and Regeneron Pharmaceuticals said.The randomised Phase 2 portion of the trial compared intravenously-administered Kevzara higher dose (400 mg), Kevzara lower dose (200 mg) and placebo.It assessed 457 hospitalised patients, who were categorised at baseline as having either "severe" illness, "critical" illness or "multi-system organ dysfunction"."Emerging evidence with Kevzara and other repurposed drugs in the Covid-19 crisis highlight the challenges of making decisions about existing medicines for new viral threats using small, uncontrolled studies," George D. Yancopoulos, Regeneron Co-Founder, President and Chief Scientific Officer, said in a statement."We await results of the ongoing Phase 3 trial to learn more about Covid-19, and better understand whether some patients may benefit from Kevzara treatment," Yancopoulos said.The trail of Roche Holding AG's Actemra by the Assistance Publique -- Hopitaux de Paris (AP-HP) -- showed that seriously ill patients due to complications from Covid-19 might benefit from the drug.While the hospital revealed the results of the small study, the findings are yet to be published.Further studies will be required to know if the drug can prove to be effective against the disease, according to researchers.Interestingly, the Kevzara trial was designed after a small, single-arm study in China among mostly severe, febrile hospitalised Covid-19 patients, which found elevated IL-6 levels, and suggested that inhibiting this pathway with the IL-6 inhibitor tocilizumab rapidly reduced fever and improved oxygenation in severe patients, allowing for successful hospital discharge.--IANSgb/arm
Dear Patron, Please provide additional information to validate your profile and continue to participate in engagement activities and purchase medicine.